Results 171 to 180 of about 209,258 (305)

Targeting WEE1 in ARID1A/TP53 Concurrent Mutant Colorectal Cancer by Exploiting R‐Loop Accumulation and DNA Repair Deficiencies

Advanced Science, EarlyView.
ARID1A, a SWI/SNF complex component, is frequently mutated in colorectal cancer (CRC). CRC with ARID1A/TP53 concurrent mutations shows marked sensitivity to WEE1 inhibition. ARID1A loss induces R‐loop‐mediated replication stress, impairs ATF3 transcription, and amplifies WEE1i‐induced DNA damage, suggesting a promising therapeutic vulnerability ...
Chi Zhang, Yanjing Zhu, Luoyan Ai, Jingyuan Wang, Shan Yu, Yichen Wang, Xiaojing Xu, Mengling Liu, Yiyi Yu, Mengxuan Zhu, Yutong Liu, Zhenghang Xu, Haojie Zhou, Huishan Li, Qihong Huang, Qing Liu, Ke Peng, Tianshu Liu   +17 more
wiley   +1 more source

The case for the therapeutic use of mechanistic/mammalian target of rapamycin (mTOR) inhibitors in xenotransplantation. [PDF]

Xenotransplantation, 2023
Maenaka A, Kinoshita K, Hara H, Cooper DKC.   +3 more
europepmc   +1 more source

Microglial HVCN1 Deficiency Improves Movement and Survival of SOD1G93A ALS Mice by Enhancing Microglial Migration and Neuroprotection

Advanced Science, EarlyView.
Hydrogen voltage gated channel 1 (HVCN1) is upregulated in microglia of both ALS patients and its mouse model. HVCN1 deficiency enhances microglial migration via suppressing Akt signaling, promotes neurotrophic capacity and motor function, and prolongs survival of the SOD1G93A ALS mice. This study identifies HVCN1 as a novel, promising druggable target
Fan Wang, Ke‐Yu Zhang, Lang‐Jian Zhu, Wei‐Jue Li, Yang Wu, Xiang Gao, Xiao‐Ru Ma, Xiu‐Hua Yin, Jian‐Bin Wu, Xiao‐Kang Ye, Zhao‐Jun Dong, Di‐Xian Wang, Zhe Zhou, Shao‐Dong Wang, Lei Han, Zhi‐Nong Jiang, Jing‐Wei Zhao   +16 more
wiley   +1 more source

Recent advances and limitations of mTOR inhibitors in the treatment of cancer. [PDF]

Cancer Cell Int, 2022
Ali ES, Mitra K, Akter S, Ramproshad S, Mondal B, Khan IN, Islam MT, Sharifi-Rad J, Calina D, Cho WC.   +9 more
europepmc   +1 more source

Navigating the Ethereal Tightrope: The Nanogenerator Manipulates Neurons for Immune Equilibrium

Advanced Science, EarlyView.
This review explores how nanogenerators modulate neuroimmune responses, offering innovative strategies for treating neurological disorders. By interfacing with neural pathways, they enable precise control of immune activity, especially via vagus nerve stimulation.
Jia Du, Rui Deng, Ya Wu, Hong‐Xia Ren, Zong‐Hong Lin, Yang‐Bao Miao   +5 more
wiley   +1 more source

Macropinocytosis and Vascularization Determine Response to mTOR Inhibitors in Lung Squamous Cell Carcinoma. [PDF]

Cancer Res
Brady MR, Matulionis N, Christofk HR, Garon EB, Lisberg A, Shackelford DB, Momcilovic M.   +6 more
europepmc   +1 more source

mTOR inhibitors are the first-choice therapy for renal angiomyolipomas secondary to tuberous sclerosis. [PDF]

J Bras Nefrol, 2023
Monich AG, Cunha MFMD, Barreto FC.
europepmc   +1 more source

Engineering Osteoimmune Responses with Functionalized Orthopedic Implants for Post‐Operative Osteosarcoma Treatment

Advanced Science, EarlyView.
Osteosarcoma is the most common primary bone tumor with limited treatment options and a terrible prognosis. This review provides a comprehensive summary of the recent development of osteoimmunomodulatory implants for post‐operative osteosarcoma treatment, of which the potential utility in evoking durable anti‐osteosarcoma immunity and accelerating bone
Yilong Dong, Lingshuang Wang, Hui Zhang, Menghuan Li, Zhong Luo, Yan Hu, Chunyuan Cai   +6 more
wiley   +1 more source

TRIM38 Suppresses Breast Cancer Progression via Modulating SQSTM1 Ubiquitination and Autophagic Flux

Advanced Science, EarlyView.
TRIM38, an E3 ubiquitin ligase, suppresses breast cancer progression by inhibiting proliferation, migration, and invasion. Downregulated in breast tumor, its loss correlates with poor prognosis. Mechanistically, TRIM38 mediates K63‐linked ubiquitination of SQSTM1/p62 at K420, disrupting SQSTM1‐LC3 interaction and blocking autophagic flux.
Shan Jiang, Lijuan Wang, Dianwen Han, Peng Su, Bing Chen, Wenjing Zhao, Tong Chen, Ning Zhang, Xiaolong Wang, Yiran Liang, Yaming Li, Chen Li, Xi Chen, Dan Luo, Qifeng Yang   +14 more
wiley   +1 more source

<i>In Silico</i> Identification of Chiral Biflavonoids as Dual PI3Kα/mTOR Inhibitors. [PDF]

ACS Omega
Nunes Azevedo FF, Freitas de Sousa FJ, Martins Negreiro J, Vieira Carletti J, Oliveira MCF, Zanatta G.   +5 more
europepmc   +1 more source